Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 186 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Galderma R&D Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Analyze Previously Collected Biopsy Samples From Participants Who Completed the "SPLASH: Split-Body Randomized Clinical Trial of Poly-L-Lactic Acid for Adipogenesis and Volumization of the Hip Dell" Study

NCT06656923
View directory record Official record
Conditions
Lateral Gluteal Depression
Interventions
Biopsies
Diagnostic Test
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01493687
View directory record Official record
Conditions
Papulopustular Rosacea (PPR)
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

NCT00763555
View directory record Official record
Conditions
Psoriasis
Interventions
CD 2027, Calcitriol Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Fridley, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 2 Interventional

Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne

NCT01106807
View directory record Official record
Conditions
Acne
Interventions
Epiduo vehicle gel, CD07223, Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Hot Springs, Arkansas • Louisville, Kentucky • Warren, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Anesthetic Effect Duration Assessment

NCT01545765
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lidocaine 7% + Tetracaine 7% cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Rochelle Park, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

NCT00598832
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene lotion 0.1%, Adapalene Lotion Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,075 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Marina del Rey, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin

NCT01046565
View directory record Official record
Conditions
Skin Manifestations
Interventions
adapalene cream 0.1%, adapalene lotion 0.1%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01355471
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 Gel, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Hot Springs, Arkansas • Miami Beach, Florida • Newnan, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Restylane® Lyft Filler Injection for Hand Rejuvenation on First Impressions

NCT04162002
View directory record Official record
Conditions
Hand Rejuvination
Interventions
Restylane® Lyft
Drug
Lead sponsor
DeNova Research
Other
Eligibility
28 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects

NCT00446043
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene/Benzoyl Peroxide
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT03989349
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Placebo, Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

NCT00919763
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 17, 2026, 4:32 AM EDT
Recruiting Not applicable Interventional

A Clinical Study to Assess Histological Changes From Treatment of Poly L-lactic Acid Biostimulator on Women at Various Menopausal Stages

NCT07342400
View directory record Official record
Conditions
Cheek Wrinkles, Menopausal Women
Interventions
Sculptra®
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

NCT03915860
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
9
States / cities
Fort Smith, Arkansas • Beverly, Massachusetts • Portsmouth, New Hampshire + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50

NCT01887860
View directory record Official record
Conditions
Skin Irritation
Interventions
Cetaphil Daily Facial Moisturizer SPF 50
Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Results available

Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

NCT02125279
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcitriol
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Years to 16 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Burbank, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Dose Range Study of CD5789 in Acne Vulgaris

NCT01616654
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream, Tazarotene 0.1% gel, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

NCT00304239
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Metvix-PDT, Vehicle-PDT
Combination Product
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Naperville, Illinois • Louisville, Kentucky • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

NCT00688064
View directory record Official record
Conditions
Severe Acne Vulgaris
Interventions
Adapalene BPO Gel associated with Doxycyline Hyclate, Vehicle Gel associated with Doxycycline Hyclate
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
28
States / cities
Oceanside, California • San Diego, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Results available

Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris

NCT00671749
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene gel, 0.3%, clindamycin/benzoyl peroxide gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Sacramento, California • Louisville, Kentucky • Warren, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Results available

Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

NCT04856904
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream, Trifarotene Vehicle Cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
17 Years to 35 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Santa Monica, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.

NCT02806414
View directory record Official record
Conditions
Rosacea
Interventions
Ivermectin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Dysport Dose-Ranging Treatment of Platysmal Bands

NCT04886167
View directory record Official record
Conditions
Platysma Bands
Interventions
AbobotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Encino, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 17, 2026, 4:32 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura

NCT01485367
View directory record Official record
Conditions
Senile Purpura
Interventions
adapalene gel 0.3%
Drug
Lead sponsor
Multispecialty Aesthetic Clinical Research Organization
Other
Eligibility
52 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Woodland Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 17, 2026, 4:32 AM EDT